Expertise in
1
conditions

Andrew R. Clamp

Manchester, ENG, GB 
Expertise in
1
conditions
Manchester, ENG, GB 

Overview

Andrew Clamp practices practicing medicine in Manchester, United Kingdom.

Mr. Clamp is highly rated in 1 condition, according to our data. His clinical expertise encompasses Ovarian Cancer, Agranulocytosis, Gastrointestinal Perforation, and Endometrial Cancer.

He is actively involved in clinical research, co-authoring 95 peer reviewed articles and participating in 12 clinical trials.

Gender

Male

Locations

Manchester, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
Enrollment Status: Completed
Publish Date: August 04, 2026
Intervention Type: Other, Drug
Study Drugs: Letrozole, Paclitaxel, Pegylated liposomal doxorubicin hydrochloride, Tamoxifen citrate, Topotecan, Trametinib dimethyl sulfoxide
Study Phase: Phase 2/Phase 3
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drugs: VS-6766, Defactinib
Study Phase: Phase 2
A Phase II Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer
A Phase II Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer
Enrollment Status: Unknown
Publish Date: April 12, 2024
Intervention Type: Drug
Study Phase: Phase 2
Randomised Phase II Trial of Olaparib, Chemotherapy or Olaparib and Cediranib in Patients With Platinum-resistant Ovarian Cancer
Randomised Phase II Trial of Olaparib, Chemotherapy or Olaparib and Cediranib in Patients With Platinum-resistant Ovarian Cancer
Enrollment Status: Completed
Publish Date: January 23, 2024
Intervention Type: Drug
Study Drugs: Olaparib, Cediranib, Paclitaxel
Study Phase: Phase 2
A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma
A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma
Enrollment Status: Unknown
Publish Date: November 08, 2023
Intervention Type: Drug
Study Drugs: AL3818, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Carboplatin
Study Phase: Phase 3
A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
Enrollment Status: Completed
Publish Date: August 19, 2022
Intervention Type: Drug
Study Drug: Prexasertib
Study Phase: Phase 2
A 3-Arm Randomised Phase II Evaluation of Cediranib in Combination With Weekly Paclitaxel or Olaparib Versus Weekly Paclitaxel Chemotherapy for Advanced Endometrial Carcinoma or for Disease Relapse Within 18 Months of Adjuvant Carboplatin-paclitaxel Chemotherapy.
A 3-Arm Randomised Phase II Evaluation of Cediranib in Combination With Weekly Paclitaxel or Olaparib Versus Weekly Paclitaxel Chemotherapy for Advanced Endometrial Carcinoma or for Disease Relapse Within 18 Months of Adjuvant Carboplatin-paclitaxel Chemotherapy.
Enrollment Status: Unknown
Publish Date: March 02, 2022
Intervention Type: Drug
Study Drugs: Paclitaxel, Cediranib, Olaparib
Study Phase: Phase 2
Single Arm Feasibility of Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer
Single Arm Feasibility of Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer
Enrollment Status: Completed
Publish Date: February 22, 2022
Intervention Type: Drug
Study Drugs: Olaparib, Cediranib
Study Phase: Early Phase 1
A Phase Ib and Randomised Phase II Trial of Pazopanib With or Without Fosbretabulin in Advanced Recurrent Ovarian Cancer
A Phase Ib and Randomised Phase II Trial of Pazopanib With or Without Fosbretabulin in Advanced Recurrent Ovarian Cancer
Enrollment Status: Terminated
Publish Date: May 17, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

95 Total Publications

Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK.
Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK.
Journal: EClinicalMedicine
Published: April 09, 2026

Frequently Asked Questions about Andrew R. Clamp

Is Andrew R. Clamp a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Andrew R. Clamp is classified as an Distinguished expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Andrew R. Clamp participate in research or clinical trials?

Yes. Andrew R. Clamp has published 95 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Andrew R. Clamp's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Clamp's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile